These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36605847)

  • 41. Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
    Usami E; Kimura M; Iwai M; Teramachi H; Yoshimura T
    Mol Clin Oncol; 2017 Jun; 6(6):955-959. PubMed ID: 28588796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spontaneous Tumour Lysis Syndrome in Mantle Cell Lymphoma: A Case Study.
    Taha N; Bhaskar G
    Cureus; 2022 Oct; 14(10):e29851. PubMed ID: 36212272
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumour lysis syndrome.
    Calvo Villas JM
    Med Clin (Barc); 2019 May; 152(10):397-404. PubMed ID: 30612747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
    Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
    J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
    Hummel M; Reiter S; Adam K; Hehlmann R; Buchheidt D
    Eur J Haematol; 2008 Apr; 80(4):331-6. PubMed ID: 18081720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
    Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Daily serum phosphate increase as early and reliable indicator of kidney injury in children with leukemia and lymphoma developing tumor lysis syndrome.
    Biró E; Erdélyi D; Varga P; Sinkó M; Bartyik K; Kovács G; Ottóffy G; Vincze F; Szegedi I; Kiss C; Szabó T
    Pediatr Nephrol; 2023 Sep; 38(9):3117-3127. PubMed ID: 36943467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spontaneous Tumor Lysis Syndrome Secondary to Metastatic Small Cell Lung Cancer.
    Koura S; Parekh V; Parikh AD; Kaur K; Dunn BK
    Cureus; 2023 Feb; 15(2):e34557. PubMed ID: 36879689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Tumor lysis syndrome and clinical guidelines].
    Ishizawa K
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):135-40. PubMed ID: 24743190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
    Bose P; Qubaiah O
    J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia.
    Prasada H
    Indian Pediatr; 2015 Jul; 52(7):613-5. PubMed ID: 26244958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Tumor lysis syndrome].
    Hagino T
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):984-8. PubMed ID: 20567098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [RASBURICASE TREATMENT FOR NEONATAL ACUTE KIDNEY INJURY - A CASE REPORT].
    Shasha-Lavsky H; Awadia P; Sheffer V; Weissman I
    Harefuah; 2021 Dec; 160(12):806-809. PubMed ID: 34957716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor lysis syndrome: a systematic review of case series and case reports.
    Firwana BM; Hasan R; Hasan N; Alahdab F; Alnahhas I; Hasan S; Varon J
    Postgrad Med; 2012 Mar; 124(2):92-101. PubMed ID: 22437219
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rasburicase in cancer-related hyperuricemia.
    Rodriguez M; Campara M; Haaf C
    Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.